BRISTOL-MYERS SQUIBB COMPANY (NYSE: BMY)

BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

Last update: 06 Oct, 10:23PM

45.14

-0.31 (-0.68%)

Add to watchlist

Previous Close	45.45
Open	45.35
Volume	16,072,750
Avg. Volume (3M)	13,630,806
Market Cap	92,445,605,888

Price / Earnings (TTM)	18.13
Price / Earnings (Forward)	7.58
Price / Sales	1.95
Price / Book	5.34

52 Weeks Range	42.96 (-4%) — 63.33 (40%)
Earnings Date	30 Oct 2025
TTM Dividend Yield	2.70%

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - General (US)	Bullish	Bearish
	Drug Manufacturers - General (Global)	Bullish	Bearish
Stock	Bristol-Myers Squibb Company	Bearish	Bearish

AIStockmoo Score

-1.3

Analyst Consensus	-0.5
Insider Activity	-1.5
Price Volatility	0.5
Technical Moving Averages	-2.5
Technical Oscillators	-2.5
Average	-1.30

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
BMY	92 B	2.70%	18.13	5.34
JNJ	460 B	1.30%	18.49	5.85
ABBV	407 B	2.10%	109.67	50.46
PFE	139 B	3.49%	12.90	1.57
GSK	90 B	0.89%	19.60	4.42
LLY	733 B	0.34%	53.53	40.22

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Sector	Healthcare
Industry	Drug Manufacturers - General
Investment Style	Large Value
% Held by Insiders	0.07%
% Held by Institutions	82.11%

52 Weeks Range	42.96 (-4%) — 63.33 (40%)
Median	47.00 (4.12%)
Total	1 Hold

Firm	Date	Target Price	Call	Price @ Call
Citigroup	01 Aug 2025	47.00 (4.12%)	Hold	44.23

Name	Avg. Buy ($)	Avg. Sell ($)	Net Quantity	Net Value ($)
GALLMAN CARI	-	45.73	-2,332	-106,642
Aggregate Net Quantity				-2,332
Aggregate Net Value ($)				-106,642
Aggregate Avg. Buy ($)				-
Aggregate Avg. Sell ($)				45.73

Name	Holder	Date	Type	Quantity	Price	Value ($)
GALLMAN CARI	Officer	02 Oct 2025	Disposed (-)	2,332	45.73	106,642
GALLMAN CARI	Officer	02 Oct 2025	Option execute	4,558	-	-

Date	Type	Details
10 Oct 2025	Announcement	Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
10 Oct 2025	Announcement	Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection
01 Oct 2025	Announcement	Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease
25 Sep 2025	Announcement	Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)
23 Sep 2025	Announcement	Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
19 Sep 2025	Announcement	Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
17 Sep 2025	Announcement	Advancing Cancer Research Brings New Hope for Patients Worldwide
17 Sep 2025	Announcement	Bristol Myers Squibb Announces Dividend
16 Sep 2025	Announcement	Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
29 Aug 2025	Announcement	Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025
29 Aug 2025	Announcement	Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
25 Aug 2025	Announcement	Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
18 Aug 2025	Announcement	Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
04 Aug 2025	Announcement	Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
04 Aug 2025	Announcement	Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
31 Jul 2025	Announcement	Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
31 Jul 2025	CNBC	Pandemic darlings Moderna, BioNTech are now on two different paths
31 Jul 2025	CNBC	Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
28 Jul 2025	Announcement	Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
25 Jul 2025	Announcement	Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
21 Jul 2025	Announcement	Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
18 Jul 2025	Announcement	Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
17 Jul 2025	Announcement	Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
17 Jul 2025	CNBC	Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Show more

TTM Dividend Yield	2.70%
5Y Average Dividend Yield	3.55%
Payout Ratio	91.04%
Expected Next Dividend Payment	Feb 2026

Ex Date	Announcement Date	Payment Date	Details
03 Jan 2025	11 Dec 2024	03 Feb 2025	0.62 Cash
04 Oct 2024	10 Sep 2024	01 Nov 2024	0.6 Cash
05 Jul 2024	18 Jun 2024	01 Aug 2024	0.6 Cash
04 Apr 2024	01 Mar 2024	01 May 2024	0.6 Cash
04 Jan 2024	06 Dec 2023	01 Feb 2024	0.6 Cash
05 Oct 2023	20 Sep 2023	01 Nov 2023	0.57 Cash
06 Jul 2023	14 Jun 2023	01 Aug 2023	0.57 Cash
06 Apr 2023	03 Mar 2023	01 May 2023	0.57 Cash
05 Jan 2023	08 Dec 2022	01 Feb 2023	0.57 Cash
06 Oct 2022	14 Sep 2022	01 Nov 2022	0.54 Cash
30 Jun 2022	15 Jun 2022	01 Aug 2022	0.54 Cash
31 Mar 2022	01 Mar 2022	02 May 2022	0.54 Cash
06 Jan 2022	13 Dec 2021	01 Feb 2022	0.54 Cash
30 Sep 2021	09 Sep 2021	01 Nov 2021	0.49 Cash
01 Jul 2021	17 Jun 2021	02 Aug 2021	0.49 Cash
31 Mar 2021	01 Mar 2021	03 May 2021	0.49 Cash
31 Dec 2020	10 Dec 2020	01 Feb 2021	0.49 Cash
01 Oct 2020	10 Sep 2020	02 Nov 2020	0.45 Cash
02 Jul 2020	11 Jun 2020	03 Aug 2020	0.45 Cash
02 Apr 2020	02 Mar 2020	01 May 2020	0.45 Cash
02 Jan 2020	06 Dec 2019	03 Feb 2020	0.45 Cash
03 Oct 2019	12 Sep 2019	01 Nov 2019	0.41 Cash
03 Jul 2019	14 Jun 2019	01 Aug 2019	0.41 Cash
04 Apr 2019	08 Mar 2019	01 May 2019	0.41 Cash
03 Jan 2019	07 Dec 2018	01 Feb 2019	0.41 Cash
04 Oct 2018	13 Sep 2018	01 Nov 2018	0.4 Cash
05 Jul 2018	15 Jun 2018	01 Aug 2018	0.4 Cash
05 Apr 2018	01 Mar 2018	01 May 2018	0.4 Cash
04 Jan 2018	07 Dec 2017	01 Feb 2018	0.4 Cash
05 Oct 2017	13 Sep 2017	01 Nov 2017	0.39 Cash
05 Jul 2017	13 Jun 2017	01 Aug 2017	0.39 Cash
05 Apr 2017	02 Mar 2017	01 May 2017	0.39 Cash
04 Jan 2017	08 Dec 2016	01 Feb 2017	0.39 Cash
05 Oct 2016	03 Aug 2016	01 Nov 2016	0.38 Cash
29 Jun 2016	07 Jun 2016	01 Aug 2016	0.38 Cash
30 Mar 2016	03 Mar 2016	02 May 2016	0.38 Cash
30 Dec 2015	08 Dec 2015	01 Feb 2016	0.38 Cash
30 Sep 2015	17 Sep 2015	02 Nov 2015	0.37 Cash
01 Jul 2015	16 Jun 2015	03 Aug 2015	0.37 Cash
01 Apr 2015	02 Mar 2015	01 May 2015	0.37 Cash
30 Dec 2014	09 Dec 2014	02 Feb 2015	0.37 Cash
01 Oct 2014	16 Sep 2014	03 Nov 2014	0.36 Cash
01 Jul 2014	17 Jun 2014	01 Aug 2014	0.36 Cash
02 Apr 2014	03 Mar 2014	01 May 2014	0.36 Cash
31 Dec 2013	19 Dec 2013	03 Feb 2014	0.36 Cash
02 Oct 2013	17 Sep 2013	01 Nov 2013	0.35 Cash
02 Jul 2013	19 Jun 2013	01 Aug 2013	0.35 Cash
Show more

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2025	0.620	1	1.37
2024	2.40	4	4.24
2023	2.28	4	4.44
2022	2.16	4	3.00
2021	1.96	4	3.14
2020	1.80	4	2.90
2019	1.64	4	2.56
2018	1.60	4	3.08
2017	1.56	4	2.55
2016	1.52	4	2.60
2015	1.48	4	2.15
2014	1.44	4	2.44
2013	0.700	2	1.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	11.38%
Operating Margin (TTM)	31.57%
Diluted EPS (TTM)	2.68
Quarterly Revenue Growth (YOY)	-5.60%
Quarterly Earnings Growth (YOY)	-95.90%

Total Debt/Equity (MRQ)	293.85%
Current Ratio (MRQ)	1.28
Operating Cash Flow (TTM)	14.31 B
Levered Free Cash Flow (TTM)	13.93 B

Return on Assets (TTM)	7.24%
Return on Equity (TTM)	31.99%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)